AlzeCure Pharma: ACD680 out-licensed to Eli Lilly - Redeye

AlzeCure has out-licensed the global rights for Alzstatin ACD680 to Eli Lilly in a deal potentially exceeding USD1bn (excluding royalties). The agreement includes a USD10m upfront payment, development and commercial milestones, and tiered mid-single-digit royalties. Given that the upfront alone corresponds to almost 60% of AlzeCure's current market cap, and that the agreement definitively validates the company's research by partnering with the world's largest pharmaceutical company, we expect a triple-digit share price reaction today.

Länk till analysen i sin helhet: https://www.redeye.se/research/1171376/alzecure-pharma-acd680-out-licensed-to-eli-lilly?utm_source=finwire&utm_medium=RSS